State Street’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
Other funds holding LYEL
OP
State Street's LYEL Position: Q3 2026 in Review
State Street increased its Lyell Immunopharma (LYEL) stake by 3.5% in Q3 2026, buying an estimated $86.3K and bringing the position to 191,807 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #3428.
State Street first reported a position in LYEL in Q3 2021 and has held it in 21 quarters since. The position peaked at $39.4M in Q3 2022. 105 funds tracked by Wall St. Rank hold LYEL as of Q3 2026.
- State Street held 191,807 shares of Lyell Immunopharma worth $1.88M as of Q3 2026.
- State Street bought 6,485 Lyell Immunopharma shares in Q3 2026, an estimated $86.3K.
- Lyell Immunopharma made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3428 holding.
- State Street first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 21 quarters since.
- State Street's Lyell Immunopharma position peaked at $39.4M in Q3 2022.
- 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2026.
Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.